Obesity is a global public health concern closely linked to cardiometabolic complications. This Comment provides our views on recent breakthroughs, emerging innovations and future needs of therapeutic interventions to counteract obesity and its associated health risks.

Researchers are exploring why some individuals are naturally super-lean and may struggle to gain weight. The causes of such constitutional thinness offer clues to the physiology of weight control.

Obesity is a global public health concern closely linked to cardiometabolic complications. This Comment provides our views on recent breakthroughs, emerging innovations and future needs of therapeutic...

Animals need to adapt behavior to balance survival with fulfillment of essential needs. Krauth et al. identify neurons in the lateral hypothalamus that, when activated, prioritize survival over other ...

Click on the article title to read more.

Neurodegenerative diseases (NDDs) represent a heterogeneous group of disorders characterized by progressive neuronal loss, which results in significant deficits in memory, cognition, motor skills, and sensory functions. As the prevalence of NDDs rises, there is an urgent unmet need for effective therapies. Current drug development approaches primarily target single pathological features of the disease, which could explain the limited efficacy observed in late-stage clinical trials. Originally developed for the treatment of obesity and diabetes, incretin-based therapies, particularly long-acting GLP-1 receptor (GLP-1R) agonists and GLP-1R–gastric inhibitory polypeptide receptor (GIPR) dual agonists, are emerging as promising treatments for NDDs. Despite limited conclusive preclinical evidence, their pleiotropic ability to reduce neuroinflammation, enhance neuronal energy metabolism and promote synaptic plasticity positions them as potential disease-modifying NDD interventions. In anticipation of results from larger clinical trials, continued advances in next-generation incretin mimetics offer the potential for improved brain access and enhanced neuroprotection, paving the way for incretin-based therapies as a future cornerstone in the management of NDDs. This Review summarizes preclinical and clinical evidence highlighting the potential of incretin-based drugs as treatments of neurodegenerative diseases, such as Alzheimer’s disease or Parkinson’s disease.

This Review summarizes preclinical and clinical evidence highlighting the potential of incretin-based drugs as treatments of neurodegenerative diseases, such as Alzheimer’s disease or Parkinson’s dise...

Objective The obesity epidemic, driven by a complex interplay of environmental and biological factors, remains a significant global health challenge. Herein, we investigate the impact of food insecu...

Click on the article title to read more.

Here, Miranda-Cervantes et al. identified pantothenate kinase 4 (PanK4) as a key regulator of muscle metabolism. Deleting PanK4 impairs fatty acid oxidation and glucose uptake, leading to glucose into...

Associate Professor Christoffer Clemmensen from the University of Copenhagen has received an ERC Consolidator Grant for a project that aims to develop new therapeutic interventions that will help peop...